

1 **Effect of sex-specific abdominal fat tissue composition on WHO/ISUP nuclear grade of**
2 **clear cell renal cell carcinoma**

3 Eser BULUT¹, Ali KÜPELİ¹, Mehmet Akif RAMAZANOĞLU², Hasan Rıza AYDIN², İbrahim SİBAL², Fatih
4 BIÇAKÇIOĞLU², Fatih YILDIRIM², Şenol ADANUR³, Salih AL³

5

6

7 ¹Department of Radiology, Faculty of Medicine, Trabzon Kanuni Training and Research Hospital,

8 Trabzon, Türkiye

9 ²Department of Urology, Faculty of Medicine, Trabzon Kanuni Training and Research Hospital,

10 Trabzon, Türkiye

11 ³Department of Urology, Faculty of Medicine, Ataturk University, Erzurum, Türkiye

12

13 ***Correspondence:** eserbulutmd@gmail.com

14

15 ORCIDs:

16 Eser BULUT: <https://orcid.org/0000-0002-6765-6552>

17 Ali KÜPELİ: <https://orcid.org/0000-0002-5322-2972>

18 Mehmet Akif RAMAZANOĞLU: <https://orcid.org/0000-0002-7637-133X>

19 Hasan Rıza AYDIN: <https://orcid.org/0000-0002-6272-6929>

20 İbrahim SİBAL: <https://orcid.org/0000-0001-6033-7500>

21 Fatih BIÇAKÇIOĞLU: <https://orcid.org/0000-0001-7175-713X>

22 Fatih YILDIRIM: <https://orcid.org/0000-0002-7544-9430>

23 Şenol ADANUR: <https://orcid.org/0000-0003-0859-1741>

24 Salih AL: <https://orcid.org/0000-0001-6999-5745>

1

2 **Funding**

3 No funding is provided in this study.

4 **Conflict of interest**

5 The authors declare that there are no conflicts of interest.

6 **Ethical approval**

7 The study was approved by the ethics review board from Trabzon Kanuni Training and Research
8 Hospital (2022/52).

9

10 **Background/aim:** To investigate the relationship between sex-related visceral obesity and
11 WHO/ISUP nuclear grade in clear cell renal cell carcinoma (ccRCC).

12 **Materials and methods:** Between January 2018 to June 2022, 95 patients (56 men and 39
13 women) with pathologically proven ccRCC who underwent abdominal computed tomography
14 (CT) examination were retrospectively examined. The patients were classified into two
15 groups: low-and high-WHO/ISUP nuclear grade ccRCC (n=58 and n=37), respectively.
16 Patient height, weight, body mass index (BMI), sex, age, subcutaneous fat area
17 (SFA), visceral fat area (VFA), total fat area (TFA) and percentage of visceral fat (VF%) were
18 recorded for the two groups.

1 **Results:** No significant differences were found in age, BMI, SFA or TFA, but VFA and VF%
2 were significantly higher in the high-grade patient group. In males, maximal tumor diameter
3 (MTD) (67.8% sensitivity and 76.9% specificity) revealed the highest AUC, and in females,
4 VF% (70.0% sensitivity and 73.7% specificity) showed the highest AUC. VF% revealed an
5 OR of 1.09 in females with high-grade ccRCC, and in males, MTD was an independent
6 predictor of ccRCC with an OR of 1.03.

7 **Conclusions:** Sex-related body fat tissue, including VFA and VF%, could be used for
8 estimating WHO/ISUP nuclear grade in patients with ccRCC, especially for females.

9 **Keywords:** Clear cell carcinoma, renal cell carcinoma, obesity, computed tomography,
10 neoplasm grading

11

12

13 **1.Introduction**

14 Renal cell carcinoma (RCC) is the most common primary malignant tumor of the kidney in
15 adults and accounts for approximately 90–95% of renal tumors [1]. Among the subtypes of
16 RCC, clear cell renal cell carcinoma (ccRCC) is the predominant subtype, and the biological
17 aggressiveness of ccRCC significantly changes the prognosis [2]. Numerous histopathological
18 features, such as TNM stage, tumor size, tumor grade, coagulative necrosis, and
19 microvascular invasion, have been determined to affect the postoperative prognosis of
20 patients with ccRCC [3]. Among these prognostic determinants, nuclear grading of carcinoma
21 is widely known as an important independent factor for cancer-specific survival in ccRCC
22 patients [4].

1 The World Health Organization/International Society of Urological Pathology
2 (WHO/ISUP) grading system for ccRCC has increased the interobserver reproducibility.
3 Additionally, it is more clinically relevant and easier to apply than the former Fuhrman
4 grading system [5]. In the WHO/ISUP grading system, grades 1–3 are defined based on
5 nucleolar prominence, and grade 4 is determined by the presence of highly atypical nuclear
6 pleomorphism, sarcomatoid or rhabdoid morphology differentiation [6]. While grades 1–2 are
7 described as low grades, grades 3–4 are defined as high grades.

8 Obesity is described as an excess of body fat. Clinically, it is usually evaluated with an
9 increase in body weight and body mass index (BMI), but obesity is quite a heterogeneous
10 condition [7]. Visceral obesity has been shown to be strongly related to different malignant
11 tumors, such as esophageal cancer, breast cancer, pancreatic cancer, lymph node metastases
12 and RCC [8-11]. It has been shown that visceral obesity is closely connected with ccRCC
13 [12]. Since the distribution of body fat is different by sex, men are prone to have more
14 visceral fat tissue, and women are prone to have more subcutaneous fat tissue [13]. Nguyen et
15 al. reported that sex differences in visceral fat tissue can affect the overall survival in patients
16 with RCC, and Hu et al. showed that females can have a higher nuclear grade related to
17 increased visceral fat tissue than males [14,15].

18 The visceral fat tissue can be exactly evaluated and measured with presurgical
19 computed tomography (CT) scans to determine visceral obesity [16]. However, there are only
20 a few studies on the relationship between sex-specific visceral fat tissue and WHO/ISUP
21 nuclear grade of ccRCC. In this study, we aimed to investigate the association between sex-
22 specific abdominal fat tissue composition according to CT and the WHO/ISUP nuclear grade
23 of ccRCC.

1 **2. Materials and methods**

2 2.1. Study population

3 This retrospective study was approved by the Institutional Ethics Committee and complied
4 with the Declaration of Helsinki. Data from January 2018 to June 2022 were obtained through
5 an electronic search of the Picture Archiving and Communication System (PACS). The
6 inclusion criteria were as follows: available presurgical CT scans, pathologically proven
7 ccRCC, and WHO/ISUP nuclear grades. The exclusion criteria were prominent artifacts on
8 CT images due to motion or metal, ccRCC without WHO/ISUP nuclear grades, lack of fit on
9 axial abdominal CT images, and recent significant weight changes. Finally, based on the
10 histopathologic analyses, 95 patients with ccRCC were included in the study. Demographic
11 data, including the patient's age, sex, height (m), and body weight (kg), were noted for the
12 patient from the medical files. Additionally, BMI (kg/m^2) was calculated as the ratio of total
13 body weight to height squared for patients in both groups.

14 2.2. CT protocol

15 Abdominal CT examinations were performed with the participants in the supine position, and
16 the patients were scanned from the diaphragm to the pubic symphysis using a 128-slice CT
17 scanner (GE Optima CT660, GE Healthcare, Milwaukee, WI, USA). All patients were
18 injected with a total of 100–120 mL of nonionic contrast agent and 30 mL of saline at a flow
19 rate of 4 mL/s via the antecubital vein with mechanical power injectors according to the portal
20 venous phase with a start delay of 70 s. The CT protocol was as follows: 120 kVp, tube
21 current of 150–165 mAs, maximum collimation of 2.5 mm, slice thickness of 1.5 mm and
22 rotation time of 0.5 s. Then, the images were reconstructed into multiplanar reformations.

23 2.3. Image analysis

24 All CT examinations were re-evaluated by two radiologists (E.B. and A.K., with 8 and 10
25 years of abdominal radiology experience, respectively) to reach a consensus without knowing

1 the WHO/ISUP nuclear grades of the lesions and demographic data. The CT images were
2 transferred to a workstation for evaluation. The maximum tumor diameters (MTD) were
3 measured at the axial slice. Then, the cross-sectional abdominal visceral (VFA) and
4 subcutaneous fat areas (SFA) were measured from CT images at the umbilical level. The
5 VFA, TFA and SFA values were obtained by setting the attenuation values for a region of
6 interest between -150 and -30 HU according to a previous study in Figure 1 [16]. While the
7 VFA was determined as fat tissue between the transversus abdominis fascia and organ
8 surfaces, the SFA was determined in the area between the abdominal fascia and the dermis.
9 Moreover, the percentage of visceral fat (VF%) was calculated using the following formula:
10 $VF\% = VFA/TFA \times 100$.

11 2.4. Histopathological assessment of nuclear grade

12 The histopathology reports were used to evaluate the WHO/ISUP nuclear grades. A total of
13 22 patients underwent partial nephrectomy, 14 patients underwent total nephrectomy, and 59
14 patients underwent radical nephrectomy. All tumors were separated into two groups: low-
15 grade ccRCC (WHO/ISUP grades 1, 2) and high-grade ccRCC (WHO/ISUP grades 3, 4).

16 2.5. Statistical analysis

17 All of the data were analyzed using the Statistical Package for the Social Sciences (SPSS 13.0
18 Statistical Software, SPSS Inc., Chicago, IL, USA) and the MedCalc package of Statistical
19 Software version 16.8 (MedCalc Software Bvba, Ostend, Belgium). Descriptive statistics,
20 including the means and ranges, were calculated for age, height, BMI, MTD, SFA, VFA,
21 TFA, and VF%. The Kolmogorov–Smirnov test was used to identify deviations from a
22 normal distribution, and appropriate tests were selected accordingly. Student's t test was used
23 to compare continuous variables. Moreover, the diagnostic performance indexes, including
24 sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV),

1 were calculated for these parameters regarding differentiation of low-grade and high-grade
2 ccRCC. Multivariate regression analysis was conducted to elucidate the independent
3 influencing factors affecting the accuracy of nuclear grading. A p value less than 0.05 was
4 considered statistically significant for all analyses.

5 **3. Results**

6 In this study, we analyzed the data of 95 patients (56 male, 39 female) with ccRCC. The
7 characteristics of the patients and their results are presented in Table 1. Tumors were observed
8 in the right kidney in 46 patients and in the left kidney in 49 patients. Fifty-eight of 95
9 ccRCCs were low-grade, and 37 were high-grade. The mean age, height (m) and weight (kg)
10 of the patients with low- and high-grade ccRCC were 59.1 ± 11 y, 1.59 ± 0.1 m, and $76.3 \pm$
11 13.4 kg and 60.3 ± 12 y, 1.60 ± 0.1 m, and 76.0 ± 8.8 kg, respectively. Additionally, the mean
12 BMI (kg/m²) values of the patients with low- and high-grade ccRCC were 29.9 ± 6.5 and 28.2
13 ± 5.3 , respectively. No statistically significant differences were found in mean height, body
14 weight or BMI between the two groups ($p > 0.186$).

15 The mean SFA, VFA, TFA, and VF% values in the patients with low- and high-grade
16 ccRCC were as follows: SFA, 216.0 cm² and 236.1 cm²; VFA, 139.5 cm² and 171.6 cm²;
17 TFA, 359.3 cm² and 407.8 cm²; and VF%, 38.8 and 43.9 , respectively. No significant
18 differences were detected in the SFA and TFA values ($p > 0.087$). While patients with high
19 grade ccRCC showed higher VF% and VFA (Figure 2a-2c), patients with low grade ccRCC
20 revealed lower VF% and VFA (Figure 3a-3c). Significant differences were observed in VFA
21 and VF% between the two groups ($p < 0.037$).

22 The characteristics of the low-grade and high-grade groups based on sex are shown in
23 Table 2. In males, there was a significant difference in only maximal tumor diameter (MTD)

1 between the low-grade and high-grade groups. In females, the VFA, VF% and MTD were
2 significantly higher in the high-grade group than in the low-grade ccRCC group.

3 The ROC curves for VFA, VF% and MTD are presented in Figure 4. The AUCs were
4 0.643, 0.627 and 0.735 for VFA, VF% and MTD, respectively. From the ROC analysis, the
5 optimal cutoff values that provided the highest sensitivity and specificity for VFA, VF% and
6 MTD were 154.8 cm², 40.7 cm² and 54.0 mm, respectively. The highest diagnostic values
7 acquired for the MTD were 69.4% sensitivity and 65.5% specificity. Using these cutoff
8 values, the diagnostic performance indexes based on sex are shown in Table 3. No significant
9 difference was observed between the AUCs of VFA, VF% and MTD ($p > 0.186$). In males,
10 MTD (67.8% sensitivity and 76.9% specificity) revealed the highest AUC, and in females,
11 VF% (70.0% sensitivity and 73.7% specificity) showed the highest AUC.

12 The logistic regression results in the univariate model for determining the associations
13 between variables and WHO/ISUP nuclear grades of ccRCC are shown in Table 4. In the
14 univariate model, VFA (OR 1.00, 95% CI 1.00–1.01, $p = 0.026$), MTD (OR 1.03, 95% CI
15 1.01–1.04, $p < 0.001$) and VF% (OR 1.03, 95% CI 1.00–1.07, $p = 0.039$) were associated with
16 high-grade ccRCC. Additionally, the logistic regression results of the multivariate model are
17 shown in Table 5. In the multivariate model, VFA (OR 0.98, 95% CI 0.97–0.99, $p = 0.004$)
18 and MTD (OR 0.95, 95% CI 0.94–0.97, $p < 0.001$) were significant predictors of high-grade
19 ccRCC.

20

21 **4. Discussion**

22 Obesity is defined as abnormal or excessive fat accumulation on the body, and BMI is a
23 preferred tool to determine the prevalence of obesity in the population, but obesity is quite a

1 heterogeneous condition [7]. Furthermore, waist circumference measurement is superior to
2 BMI in determining visceral obesity [17]. Abdominal fat distribution, including VFA and
3 SFA, can be precisely measured using MRI or CT to determine abdominal obesity. As an
4 active hormonal tissue, visceral fat tissue releases inflammatory cytokines, insulin, and
5 insulin-like growth factor, and these agents can drive the proliferation of cancer cells [18]. It
6 has been reported that visceral obesity carries a risk of malignant tumor development,
7 including tumors such as esophageal cancer, breast cancer, pancreatic cancer, lymph node
8 metastases and RCC [8-11].

9 It has been shown that visceral obesity is a significant predictor of survival in
10 metastatic RCC and has a high impact on survival, prognosis, subtype and grade of RCC [18-
11 20]. Additionally, it has been reported that VFA is an independent prognostic factor for
12 ccRCC, high-grade RCC and recurrence-free survival in ccRCC [11,12,20]. In contrast,
13 Martini et al. showed that higher total fat was related to survival in metastatic RCC, and
14 Maurits et al. reported that worse overall survival was detected in stage IV RCC patients with
15 lower amounts of visceral adipose tissue [21,22]. Clear cell renal cell carcinoma is the most
16 common and most lethal RCC variant [2]. BMI seems to be an independent predictor of clear-
17 cell histology in RCC. Additionally, the odds of having ccRCC can increase with increased
18 BMI [12].

19 Although there are several pathological prognostic factors, including nuclear grade,
20 tumor staging, lymphovascular invasion and necrosis, one of the most common prognostic
21 parameters arises from the nuclear grading system for detecting the aggressiveness of ccRCC
22 [3-4]. WHO/ISUP nuclear grading focuses on nucleolar prominence, which is a component of
23 the Fuhrman grading. More objective and simple criteria are used in WHO/ISUP grades 1-3
24 than in the Fuhrman grading system, which assigns the same importance to nucleolar

1 prominence, nuclear size, and nuclear shape [23]. Needle biopsies are commonly used to
2 diagnose ccRCC; however, they have some limitations in determining nuclear grading,
3 especially in low-grade cases and large heterogeneous tumors [24]. Therefore, there is a need
4 for the accurate prediction of nuclear grade without radical procedures. In this study, we
5 investigated the effect of visceral obesity on predicting WHO/ISUP nuclear grade.

6 We found that there were no statistically significant differences in terms of height, body
7 weight, BMI, TFA or SFA between the low- and high-grade groups, whereas VFA and
8 VFA% were significantly higher in patients with high-grade ccRCC. Additionally, the MTD
9 was significantly greater in high-grade ccRCC patients than in low-grade patients. In males,
10 the MTD was the only parameter that was significantly higher in the high-grade group than in
11 the low-grade group. In females, the MTD, VFA and VF% were significantly higher in the
12 high-grade group than in the low-grade group. Hu et al. reported that any of the variables
13 showed a significant difference between the low-grade and high-grade groups in males, and
14 the VFA and VF% revealed significantly greater degrees of elevation in the high-grade group
15 than in the low-grade group in females [15]. While HU et al. used the Fuhrman nuclear
16 grading system in the pathological grading of ccRCC in their multicenter study, we used the
17 WHO/ISUP nuclear grading system which is a new classification system in our single center
18 study [15].

19 In our study, the highest diagnostic values provided by MTD showed 69.4%
20 sensitivity and 65.5% specificity. Although the MTD exhibited the highest AUC among the
21 examined variables across both groups, no significant difference was observed between the
22 AUCs. Additionally, no significant difference was found between the AUCs of MTD, VFA
23 and VF% in the male and female groups. In males, the highest diagnostic values provided by

1 MTD showed 68.7% sensitivity and 76.9% specificity. In females, the highest diagnostic
2 values provided by VF% showed 70.0% sensitivity and 79.7% specificity.

3 In this study, we separated the patients according to their sex, and then lesions were
4 classified into subgroups by nuclear grade to prevent an effect of sex when considering the
5 true effect of visceral fat tissue in predicting prognosis in ccRCC. Although there was no
6 significant difference among VFA and VF% in males, the VFA and VF% were significantly
7 higher in females between low and high nuclear grades of ccRCC. There are differences in the
8 distribution of body fat by gender, such that men are prone to have more visceral fat tissue
9 and women are prone to have more fat in the subcutaneous tissue [13]. Additionally, fat tissue
10 secretes inflammatory cytokines that alter metabolic demands and increase the risk of cancer
11 development [25]. Since women have a low tolerance for visceral fat storage, this may cause
12 an increased risk of cancer in women. In this study, we found that VF% had the highest OR in
13 the univariate and multivariate analyses.

14 Differences in the level of the sex hormone estrogen may provide an explanation for
15 the association of VF% with increased risk of ccRCC. Estrogen can ease fat tissue deposition
16 and is more abundant in women. It has alpha and beta receptors. It has been reported that the
17 beta receptor reduces cell growth, migration and invasion ability and increases apoptosis in
18 RCC [13]. Additionally, an increased alpha to beta receptor ratio restricts visceral fat tissue
19 deposition in premenopausal women [26]. In this study, we could not investigate the blood
20 estrogen level.

21 This study had a number of limitations. The first limitation was that the use of
22 retrospective analysis could lead to selection bias. The second limitation was that the number
23 of patients was also relatively small. The third limitation was that the CT images were
24 evaluated based on a consensus, and we did not evaluate the inter- or intraobserver variability

1 in this study. Fourth, there were no laboratory parameters, such as blood estrogen data and
2 lipid panels. Fifth, the adipose tissue area was evaluated from a single CT section instead of
3 via a volume calculation.

4 In conclusion, significant differences were found in VFA and VF% in high-grade
5 ccRCC in female patients unlike in male patients in this study. The sex-specific visceral fat
6 composition represented by VFA and VF% could be used for estimating WHO/ISUP nuclear
7 grade in patients with ccRCC. However, extensive studies with larger populations are needed
8 to clearly confirm the relationships between sex-specific differences in visceral obesity and
9 ccRCC.

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 **References**

- 2 1. Medina-Rico M, Ramos HL, Lobo M, Romo J, Prada JG. Epidemiology of renal cancer in
3 developing countries: Review of the literature. *Canadian Urological Association Journal*
4 2018; 12 (3): E154-E162. [https://doi: 10.5489/cuaj.4464](https://doi.org/10.5489/cuaj.4464)
- 5 2. Muglia, V.F. Prando, A. Renal cell carcinoma: Histological classification and correlation
6 with imaging findings. *Radiologia Brasileira*. 2015; 48 (3): 166–74. [https://doi: 10.1590/0100-](https://doi.org/10.1590/0100-3984.2013.1927)
7 3984.2013.1927
- 8 3. Mattila KE, Vainio P, Jaakkola PM. Prognostic factors for localized clear cell renal cell
9 carcinoma and their application in adjuvant therapy. *Cancers (Basel)* 2022; 14 (1): 239.
10 [https://doi: 10.3390/cancers14010239](https://doi.org/10.3390/cancers14010239)
- 11 4. Mancini V, Battaglia M, Ditunno P, Palazzo S, Lastilla G et al. Current insights in renal
12 cell cancer pathology. *Journal of Urologic Oncology* 2008; 26 (3): 225-238. [https://doi:](https://doi.org/10.1016/j.urolonc.2007.05.017)
13 10.1016/j.urolonc.2007.05.017
- 14 5. Browning L, Colling R, Verrill C. WHO/ISUP grading of clear cell renal cell carcinoma
15 and papillary renal cell carcinoma; validation of grading on the digital pathology platform and
16 perspectives on reproducibility of grade. *Diagnostic Pathology* 2021; 16 (1): 75. [https://doi:](https://doi.org/10.1186/s13000-021-01130-2)
17 10.1186/s13000-021-01130-2
- 18 6. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO
19 Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal,
20 Penile, and Testicular Tumours. *European Urology* 2016; 70 (1): 93-105. [https://doi:](https://doi.org/10.1016/j.eururo.2016.02.029)
21 10.1016/j.eururo.2016.02.029
- 22 7. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight
23 and obesity. *Journal of Chronic Diseases* 1972; 25 (6): 329–343. [https://doi: 10.1016/0021-](https://doi.org/10.1016/0021-9681(72)90027-6)
24 9681(72)90027-6
- 25 8. Okumura S, Kaido T, Hamaguchi Y, Kobayashi A, Shirai H et al. Visceral adiposity and
26 sarcopenic visceral obesity are associated with poor prognosis after resection of pancreatic
27 cancer. *Annals of Surgical Oncology* 2017; 24 (12): 3732-3740. [https://doi: 10.1245/s10434-](https://doi.org/10.1245/s10434-017-6077-y)
28 017-6077-y
- 29 9. Yip C, Goh V, Davies A, Gossage J, Mitchell-Hay R et al. Assessment of sarcopenia and
30 changes in body composition after neoadjuvant chemotherapy and associations with clinical

- 1 outcomes in oesophageal cancer. *European Radiology* 2014; 24 (5): 998-1005. [https://doi:](https://doi:10.1007/s00330-014-3110-4)
2 10.1007/s00330-014-3110-4
- 3 10. Zhu Y, Wang HK, Zhang HL, Yao XD, Zhang SL et al. Visceral obesity and risk of high
4 grade disease in clinical t1a renal cell carcinoma. *Journal Of Urological Surgery*2013; 189
5 (2): 447-453. [https://doi: 10.1016/j.juro.2012.09.030](https://doi:10.1016/j.juro.2012.09.030)
- 6 11. Keehn A, Srivastava A, Maiman R, Taylor J, DiVito J et al. The relationship between
7 visceral obesity and the clinicopathologic features of patients with small renal masses. *Journal*
8 *of Endourology* 2015; 29 (3): 372-376. [https://doi: 10.1089/end.2014.0512](https://doi:10.1089/end.2014.0512)
- 9 12. Kaneko G, Miyajima A, Yuge K, Yazawa S, Mizuno R et al. Visceral obesity is
10 associated with better recurrence-free survival after curative surgery for Japanese patients
11 with localized clear cell renal cell carcinoma. *Japanese Journal of Clinical Oncology* 2015; 45
12 (2): 210-216. [https://doi: 10.1093/jjco/hyu193](https://doi:10.1093/jjco/hyu193)
- 13 13. Palmer BF, Clegg DJ. The sexual dimorphism of obesity. *Molecular and Cellular*
14 *Endocrinology* 2015; 402: 113-119. [https://doi: 10.1016/j.mce.2014.11.029](https://doi:10.1016/j.mce.2014.11.029)
- 15 14. Nguyen GK, Mellnick VM, Yim AK, Salter A, Ippolito JE. Synergy of sex differences in
16 visceral fat measured with CT and tumor metabolism helps predict overall survival in patients
17 with renal cell carcinoma. *Radiology* 2018; 287 (3): 884-892. [https://doi:](https://doi:10.1148/radiol.2018171504)
18 10.1148/radiol.2018171504
- 19 15. Hu Z, Wu J, Lai S, Xu Y, Zhan J et al. Clear cell renal cell carcinoma: the value of sex-
20 specific abdominal visceral fat measured on CT for prediction of Fuhrman nuclear grade.
21 *European Radiology* 2020; 30 (7): 3977-3986. [https://doi: 10.1007/s00330-020-06747-3](https://doi:10.1007/s00330-020-06747-3)
- 22 16. Kupeli A, Danisan G, Kocak M, Taskent I, Balcı IG et al. Gastric wall fat halo sign in
23 patients without intestinal disease. *Clinical Imaging* 2019; 54: 31-36. [https://doi:](https://doi:10.1016/j.clinimag.2018.11.013)
24 10.1016/j.clinimag.2018.11.013
- 25 17. Wei J, Liu X, Xue H, Wang Y, Shi Z. Comparisons of Visceral Adiposity Index, Body
26 Shape Index, Body Mass Index and Waist Circumference and Their Associations with
27 Diabetes Mellitus in Adults. *Nutrients* 2019; 11 (7): 1580. [https://doi: 10.3390/nu11071580](https://doi:10.3390/nu11071580)
- 28 18. Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit JM et al. Visceral fat area as a new
29 independent predictive factor of survival in patients with metastatic renal cell carcinoma

1 treated with antiangiogenic agents. *Oncologist* 2011; 16 (1): 71-81. [https://doi:](https://doi:10.1634/theoncologist.2010-0227)
2 10.1634/theoncologist.2010-0227

3 19. Kaneko G, Miyajima A, Yuge K, Yazawa S, Mizuno R et al. Visceral obesity is
4 associated with better recurrence-free survival after curative surgery for Japanese patients
5 with localized clear cell renal cell carcinoma. *Japanese Journal of Clinical Oncology* 2015; 45
6 (2): 210-216. [https://doi: 10.1093/jjco/hyu193](https://doi:10.1093/jjco/hyu193)

7 20. Wang HK, Song XS, Cheng Y, Qu YY, Zhang SL et al. Visceral fat accumulation is
8 associated with different pathological subtypes of renal cell carcinoma (RCC): a multicentre
9 study in China. *BJU International* 2014; 114 (4): 496-502. [https://doi: 10.1111/bju.12592](https://doi:10.1111/bju.12592)

10 21. Martini DJ, Olsen TA, Goyal S, Liu Y, Evans ST et al. Body composition variables as
11 radiographic biomarkers of clinical outcomes in metastatic renal cell carcinoma patients
12 receiving immune checkpoint inhibitors. *Frontiers in Oncology* 2021; 11: 707050. [https://doi:](https://doi:10.3389/fonc.2021.707050)
13 10.3389/fonc.2021.707050

14 22. Maurits JSF, Sedelaar JPM, Mulders PFA, Aben KKH, Kiemeny LALM et al. Skeletal
15 muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell
16 cancer - A multicenter population-based cohort study. *Clinical Nutrition* 2022; 41 (1): 131-
17 143. [https://doi: 10.1016/j.clnu.2021.11.012](https://doi:10.1016/j.clnu.2021.11.012)

18 23. Sika-Paotonu D, Bethwaite PB, McCredie MR, William Jordan T, Delahunt B. Nucleolar
19 grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. *The American*
20 *Journal of Surgical Pathology* 2006; 30 (9): 1091-1096. [https://doi:](https://doi:10.1097/01.pas.0000209833.69972.2b)
21 10.1097/01.pas.0000209833.69972.2b

22 24. Murase Y, Iwata H, Takahara T, Tsuzuki T. The highest Fuhrman and WHO/ISUP grade
23 influences the Ki-67 labeling index of those of grades 1 and 2 in clear cell renal cell
24 carcinoma. *Pathology International* 2020; 70 (12): 984-991. [https://doi: 10.1111/pin.13025](https://doi:10.1111/pin.13025)

25 25. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development
26 in obesity. *Nature Reviews Cancer* 2011; 11 (12): 886-895. [https://doi: 10.1038/nrc3174](https://doi:10.1038/nrc3174)

27 26. Yu CP, Ho JY, Huang YT, Cha TL, Sun GH et al. Estrogen inhibits renal cell carcinoma
28 cell progression through estrogen receptor- β activation. *PLoS One* 2013; 8 (2): e56667.
29 [https://doi: 10.1371/journal.pone.0056667](https://doi:10.1371/journal.pone.0056667)

1

2 Table 1: The baseline characteristics and visceral fat measurements of patients

	Total	Low grade (n=58)	High grade (n=37)	p value
Age (y)	59.6 ± 11.7 (34–86)	59.1 ± 11.4 (35–86)	60.3 ± 12.2 (34–86)	0.606
Sex (M/F)	56/39	39/19	17/20	0.040
Height (cm)	159.8 ± 7.7 (143–180)	159.4 ± 8.5 (143–180)	160.4 ± 6.2 (143–170)	0.534
Weight (kg)	76.2 ± 11.8 (52–114)	76.3 ± 13.4 (52–114)	76.0 ± 8.8 (60–93)	0.902
BMI (kg/m ²)	29.3 ± 6.1 (18.9–46.6)	29.9 ± 6.5 (18.9–46.4)	28.2 ± 5.3 (19.7–46.6)	0.186
MTD (mm)	61.8 ± 36.8 (16–194)	49.1 ± 34.2 (16–112)	82.4 ± 44.0 (22–194)	<0.001
VFA (cm ²)	152.0 ± 69.8 (12.8–296.7)	139.5 ± 71.6 (12.8–296.7)	171.6 ± 62.9 (15.0–272.8)	0.002
SFA (cm ²)	223.8 ± 112.7 (18.4–606.1)	216.0 ± 112.6 (29.8–606.1)	236.1 ± 113.1 (18.4–552.5)	0.321
TFA (cm ²)	378.2 ± 154.1 (33.4–863.4)	359.3 ± 154.1 (54.9–863.4)	407.8 ± 151.5 (33.4–739.2)	0.087
VF%	40.8 ± 12.0 (15.8–76.3)	38.8 ± 12.1 (15.8–76.3)	43.9 ± 11.2 (25.2–71.2)	0.037

3

4 BMI: body mass index; MTD: maximal tumor diameter; VFA: visceral fat area; SFA:
5 subcutaneous fat area; TFA: total fat area; VF%: percentage of visceral fat

6

7

8

9

10

11

12

13

1

2 Table 2: The characteristics of the low-grade and high-grade groups based on sex

3

	Male (n=56)	Female (n=39)	p value	Male			Female		
				Low grade (n=39)	High grade (n=17)	p value	Low grade (n=19)	High grade (n=20)	p value
Age (y)	59.5 ± 11.1	59.7 ± 12.6	0.925	58.7 ± 11.0	61.3 ± 11.4	0.441	60.0 ± 12.4	59.5 ± 13.1	0.894
Height (cm)	160.7 ± 6.8	158.5 ± 8.7	0.174	159.5 ± 6.2	163.3 ± 7.6	0.056	159.1 ± 12.1	157.9 ± 5.8	0.687
Weight (kg)	76.0 ± 11.6	76.5 ± 12.2	0.840	75.0 ± 12.8	78.2 ± 8.0	0.354	79.0 ± 14.3	74.2 ± 12.6	0.227
BMI (kg/m ²)	27.9 ± 5.6	31.2 ± 6.2	0.010	28.7 ± 6.1	26.2 ± 4.6	0.141	32.5 ± 6.5	29.9 ± 5.8	0.199
MTD (mm)	64.3 ± 38.0	58.4 ± 35.2	0.450	52.1 ± 26.2	93.9 ± 46.2	<0.001	42.8 ± 18.4	73.9 ± 41.1	0.006
VFA (cm ²)	148.5 ± 74.4	157.1 ± 63.3	0.558	144.8 ± 73.6	156.9 ± 77.7	0.582	128.5 ± 68.0	184.2 ± 45.2	0.005
SFA (cm ²)	187.0 ± 85.8	276.7 ± 126.0	<0.001	180.7 ± 75.2	201.4 ± 107.3	0.412	288.3 ± 141.6	265.6 ± 111.7	0.581
TFA (cm ²)	339.5 ± 137.8	433.8 ± 161.1	0.003	331.4 ± 124.9	358.3 ± 166.3	0.505	416.8 ± 191.4	349.9 ± 127.1	0.529
VF%	43.3 ± 11.0	37.2 ± 12.6	0.014	42.3 ± 10.9	45.4 ± 12.3	0.338	31.4 ± 11.5	42.6 ± 11.3	0.004

4

5 BMI: body mass index; MTD: maximal tumor diameter; VFA: visceral fat area; SFA:
6 subcutaneous fat area; TFA: total fat area; VF%: percentage of visceral fat

7

8

9

10

11

12

1

2 Table 3: Results of receiver operating characteristic analysis

	Total			Gender					
				Male (n=56)			Female (n=39)		
	VFA	VF%	MTD	VFA	VF%	MTD	VFA	VF%	MTD
AUC	0.643	0.627	0.735	0.552	0.588	0.780	0.753	0.787	0.733
Cutoff Level	154.8	40.7	54.0	157.7	42.7	63.0	164.7	36.2	51.0
Sensitivity (%)	67.5	67.5	69.4	58.8	64.7	68.7	70.0	70.0	65.0
Specificity (%)	55.1	58.6	65.5	61.4	53.8	76.9	73.6	73.7	78.9
PPV(%)	49.0	51.0	55.6	40.0	37.9	55.0	73.7	73.7	76.5
NPV(%)	72.7	73.9	77.6	77.4	77.8	85.7	70.0	70.0	68.2

3

4 AUC: *area under the curve*; MTD: maximal tumor diameter; VFA: visceral fat area; VF%:
5 percentage of visceral fat; PPV: positive predictive value; NPV: negative predictive value

6

7

8

9

10

11

12

13

14

15

16

1

2 Table 4: Univariate analysis for predicting high-grade ccRCC

3

	Total (n=95)			Male (n=56)			Female (n=39)		
	OR	%95 CI	p value	OR	%95 CI	p value	OR	%95 CI	p value
Age, years	1.00	0.97-1.04	0.643	1.02	0.96-1.07	0.429	0.99	0.95-1.05	0.890
MTD (mm)	1.03	1.01-1.04	<0.001	1.03	1.01-1.06	<0.001	1.03	1.00-1.07	0.002
VFA, cm ²	1.00	1.00-1.01	0.026	1.00	0.99-1.01	0.574	1.01	1.00-1.04	0.003
SFA, cm ²	1.00	0.99-1.00	0.393	1.00	0.99-1.01	0.402	0.99	0.98-1.00	0.568
TFA, cm ²	1.00	0.99-1.00	0.131	1.00	0.99-1.01	0.494	1.00	0.99-1.00	0.514
VF%	1.03	1.00-1.07	0.039	1.02	0.97-10.7	0.332	1.09	1.02-1.17	0.002

4

5 MTD: maximal tumor diameter; VFA: visceral fat area; SFA: subcutaneous fat area; TFA:
6 total fat area; VF%: percentage of visceral fat

7

8

9

10

11

12

13

14

15

1

2 Table 5: Multivariate analysis for predicting high-grade ccRCC

	Total (n=95)			Male (n=56)			Female (n=39)		
	OR	%95 CI	p value	OR	%95 CI	p value	OR	%95 CI	p value
MTD (mm)	0.95	0.94-0.97	<0.001	0.95	0.93-0.98	0.001	0.93	0.88-0.98	0.011
VFA, cm ²	0.98	0.97-0.99	0.004	0.99	0.97-1.00	0.142	0.97	0.95-0.99	0.022
VF%	1.00	0.95-1.06	0.765	1.00	0.92-1.08	0.970	0.95	0.87-1.04	0.353

3

4 MTD: maximal tumor diameter; VFA: visceral fat area; VF%: percentage of visceral fat

5

6

7

8

9

10

11

12

13

14


15

1

2 **Figure Legends;**

3 **Figure 1.** Automatic calculation of visceral and subcutaneous fatty tissue in the range of -150
4 and -30 HU on the CT image in the axial plane at the level of the umbilicus.

5



6

7


8

9

1 **Figure 2.** 44-year-old man with right-sided clear cell renal cell carcinoma. Contrast enhanced
2 CT (a) shows a tumour (arrow) in the right and with a VF% of 57.2% (b). Histologic
3 photomicrograph confirms WHO/ISUP nuclear grade IV ccRCC on high-power ($\times 400$;
4 haematoxylin-eosin stain) magnification (c).



5
6
7
8




1

2

3

4



1

2

3

4

5

6

7

8

9

10

1 **Figure 3.** 49-year-old man with right-sided clear cell renal cell carcinoma. Contrast enhanced
2 CT (a) shows a tumour (arrow) in the right and with a VF% of 39.2% (b). Histologic
3 photomicrograph confirms WHO/ISUP nuclear grade I ccRCC on high-power ($\times 400$;
4 haematoxylin-eosin stain) magnification (c).

5




6

7

8


B



1

2

3



1

2

3

4

5

6


7

8

9

10

1 **Figure 4.** The graph shows the receiver operating characteristics of both genders.



2

3

4

5

6

7

8

9

1

2